Literature DB >> 7988626

Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children.

E Jacqz-Aigrain1, C Montes, P Brun, C Loirat.   

Abstract

The pharmacokinetic parameters of cyclosporine (CsA) were determined in 23 kidney transplant recipients and 19 children with nephrotic syndrome, after intravenous and oral administration. The mean bioavailability was 39%, blood clearance was 0.55 l.h-1.kg-1 and volume of distribution at steady-state was 2.77 l.kg-1. The absorption profile was monophasic (67%), biphasic (29%) or poor (4%). The maximum blood concentration of CsA was significantly higher in children with a monophasic profile than in children with a biphasic profile (550 vs 380 ng.ml-1). Blood clearance was significantly higher in the transplant recipients than in the patients with nephrotic syndrome (0.65 vs 0.43 l.h-1.kg-1. Although age, haematocrit, creatinine clearance, serum albumin and cholesterol differed between the two groups, only haematocrit and creatinine clearance were significantly (negatively) correlated with CsA clearance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988626     DOI: 10.1007/BF00193480

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  The pharmacokinetics of cyclosporine A in uremic patients.

Authors:  A Lindberg; B Odlind; G Tufveson; B Lindström; J Gabrielsson
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 2.  Significance of cyclosporine pharmacokinetics.

Authors:  J Grevel
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

3.  Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: a pharmacokinetic study.

Authors:  T M Phillips; S A Karmi; S C Frantz; H F Henriques
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

4.  Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies.

Authors:  T G Rosano; M A Pell; B M Freed; M T Dybas; N Lempert
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients.

Authors:  E Langhoff; S Madsen; H Flachs; K Olgaard; J Ladefoged; E F Hvidberg
Journal:  Transplantation       Date:  1985-01       Impact factor: 4.939

6.  Intra- and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplants.

Authors:  A Lindholm; S Henricsson
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

7.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.

Authors:  J Combalbert; I Fabre; G Fabre; I Dalet; J Derancourt; J P Cano; P Maurel
Journal:  Drug Metab Dispos       Date:  1989 Mar-Apr       Impact factor: 3.922

8.  A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children.

Authors:  A Tejani; M Suthanthiran; A Pomrantz
Journal:  Nephron       Date:  1991       Impact factor: 2.847

9.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

Authors:  L Pichard; I Fabre; G Fabre; J Domergue; B Saint Aubert; G Mourad; P Maurel
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

10.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  6 in total

Review 1.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 2.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

3.  Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.

Authors:  Wei Zhao; Valéry Elie; Véronique Baudouin; Albert Bensman; Jean Luc André; Karine Brochard; Françoise Broux; Mathilde Cailliez; Chantal Loirat; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

Review 4.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 6.  Calcineurin inhibitors in pediatric renal transplant recipients.

Authors:  Guido Filler
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.